Earnings results for Medicenna Therapeutics (NASDAQ:MDNA)
Medicenna Therapeutics Corp. is estimated to report earnings on 05/21/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.07. The reported EPS for the same quarter last year was $-0.05.
Medicenna Therapeutics last posted its quarterly earnings results on February 12th, 2021. The reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.02. Medicenna Therapeutics has generated ($0.19) earnings per share over the last year. Medicenna Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, May 21st, 2021 based off prior year’s report dates.
Analyst Opinion on Medicenna Therapeutics (NASDAQ:MDNA)
4 Wall Street analysts have issued ratings and price targets for Medicenna Therapeutics in the last 12 months. Their average twelve-month price target is $10.00, predicting that the stock has a possible upside of 200.30%. The high price target for MDNA is $12.00 and the low price target for MDNA is $8.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Medicenna Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $10.00, Medicenna Therapeutics has a forecasted upside of 200.3% from its current price of $3.33. Medicenna Therapeutics has received no research coverage in the past 90 days.
Dividend Strength: Medicenna Therapeutics (NASDAQ:MDNA)
Medicenna Therapeutics does not currently pay a dividend. Medicenna Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Medicenna Therapeutics (NASDAQ:MDNA)
In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock. Only 3.90% of the stock of Medicenna Therapeutics is held by institutions.
Earnings and Valuation of Medicenna Therapeutics (NASDAQ:MDNA
Earnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.19) to ($0.25) per share. The P/E ratio of Medicenna Therapeutics is -16.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Medicenna Therapeutics is -16.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Medicenna Therapeutics has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here